The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance

[1]  F. Boccardo,et al.  Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients , 2019, Cancers.

[2]  Martin L. Miller,et al.  UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma , 2019, Cell.

[3]  Z. Zhang,et al.  Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China. , 2019, Public health.

[4]  I. Kyrochristos,et al.  Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapy. , 2019, Drug discovery today.

[5]  Philip Scheltens,et al.  The plasma peptides of ovarian cancer , 2018, Clinical Proteomics.

[6]  T A Chan,et al.  Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[8]  A. Schally,et al.  Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth , 2018, Proceedings of the National Academy of Sciences.

[9]  Zheng Wang,et al.  Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers , 2018, Nature Communications.

[10]  Yingyan Yu,et al.  Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis , 2018, Cancer management and research.

[11]  A. Tewari,et al.  Intratumor heterogeneity in prostate cancer. , 2018, Urologic oncology.

[12]  Christopher T. Saunders,et al.  Strelka2: fast and accurate calling of germline and somatic variants , 2018, Nature Methods.

[13]  Steven J. M. Jones,et al.  Comprehensive Characterization of Cancer Driver Genes and Mutations , 2018, Cell.

[14]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[15]  Krishna R. Kalari,et al.  A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate–prednisone , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  D. Mikhaylenko,et al.  Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer , 2017, Current genomics.

[17]  Doron Lipson,et al.  High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. , 2017, Cancer research.

[18]  N. McGranahan,et al.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.

[19]  M. Berger,et al.  Precision oncology: Charting a path forward to broader deployment of genomic profiling , 2017, PLoS medicine.

[20]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[21]  Nilgun Donmez,et al.  Clonality inference in multiple tumor samples using phylogeny , 2015, Bioinform..

[22]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[23]  E. Mroz,et al.  Intra-tumor Genetic Heterogeneity and Mortality in Head and Neck Cancer: Analysis of Data from The Cancer Genome Atlas , 2015, PLoS medicine.

[24]  N. McGranahan,et al.  Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. , 2015, Cancer cell.

[25]  A. Bouchard-Côté,et al.  PyClone: statistical inference of clonal population structure in cancer , 2014, Nature Methods.

[26]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[27]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[28]  E. Mroz,et al.  MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. , 2013, Oral oncology.

[29]  Jiri Bartek,et al.  Replication stress links structural and numerical cancer chromosomal instability , 2013, Nature.

[30]  K. Silverstein,et al.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. , 2013, Cancer research.

[31]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[32]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[33]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[34]  Carlo C. Maley,et al.  Clonal evolution in cancer , 2012, Nature.

[35]  M. Goto,et al.  Mucins in human neoplasms: Clinical pathology, gene expression and diagnostic application , 2011, Pathology international.

[36]  P. Nelson,et al.  Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants , 2011, Clinical Cancer Research.

[37]  Sarat Chandarlapaty,et al.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.

[38]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[39]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[40]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[41]  M. Poupon,et al.  Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft , 2004, British Journal of Cancer.

[42]  Yoshio Matsumoto,et al.  Identification of Neuropeptide W as the Endogenous Ligand for Orphan G-protein-coupled Receptors GPR7 and GPR8* , 2002, The Journal of Biological Chemistry.

[43]  Claude-Alain H. Roten,et al.  Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..

[44]  E. Latulippe,et al.  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. , 2004, The American journal of pathology.

[45]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[46]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..